|Articles|January 20, 2021

Creating a Cheaper COVID-19 Test to Serve Underrepresented Communities

Author(s)Killian Meara

Affordable, accurate testing that can detect new variants of the disease is paramount in halting it’s spread.

PathogenDx, a technology company that delivers viral testing solutions for various bacterial and fungal infections, has developed a test for the coronavirus disease 2019 (COVID-19) using a one-of-a-kind microarray.

In a discussion surrounding the company and its testing kit, the CEO Milan Patel talks about the company’s key goals and the issues inflicting current COVID-19 testing.

“Ramp it up nationally, make it affordable so that the masses can have access to testing, especially in rural and urban America. If you look at metropolitan areas, they took the lion’s share of the testing, but the rest of America got left behind,” Patel said.

One of the major aims that PathogenDx has is providing their test to a larger population that may not have the ability to get tested. Due to their products cheaper cost, they are able to serve these underrepresented communities.

When asked how the company is able to create a more affordable test, Patel said “If you pool multiple samples in that one test, then effectively the cost will drop by 60%. So, you can effectively get the price of a test somewhere between $10 to $15 when you pool it and that’s how you drive the cost down.”


Related to this article

FAQ: What You Need to Know About West Nile Virus in 2026
After 2 adults died of West Nile virus in central North Carolina this month, this FAQ explains how the mosquito-borne virus spreads, who faces the greatest risk of severe neuroinvasive disease, and how clinicians can diagnose, manage, and help prevent infection when no vaccine or antiviral treatment exists.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.